Following the success of anti-CTLA4 and PD(L)1 therapies over the last five years or so, there is much time and attention being focused on addressing a key question, namely – what’s the next viable checkpoint target?
There are quite a few possibilities emerging, although to be fair, some of them will no doubt go by the wayside over the next year or two. There has already been quite a bit of attrition since 2015/16. Figuring out which ones will be a target versus being a useful marker is also an important aspect of new product development.
Competition is a fine thing – as long as they’re going in the direction you want to go.
For most of our ASCO coverage over the last few years we have tended to include a variety of approaches in the pre-conference Preview series that can run from a tumour type, a up and coming modality, an emerging target, and various other ways of looking at or making sense of the sea of data.
Here, we take a look at an IO target that is receiving much interest and explore what we know and where this might be headed… and ask whether the early promise is living up to the billing in practice?